Haohong Pharmaceutical
Apalutamide intermediates，Abemaciclib intermediates，Alectinib intermediates
- Founded
- 2021
- Headquarters
- Name:Xu Tianxia Email: Xutx@haohong-pharma.com Tel: +86 180-6854-1569 WhatsApp: +86 180-6854-1569 Address: Block B, building 3, accelerator, high tech Zone, Qihe County, De Zhou City, Shandong Province, China
- Factory Area
- 3000㎡
- Employees
- 75
- Export Ratio
- 40%
- Website
- www.haohong-pharma.com
- Contact via WhatsApp
About Us
Haohong (Qihe) Pharmaceutical Technology Co., Ltd. is located in the High-tech Zone of Qihe County, Shandong Province, adjacent to the Yellow River and within the Jinan Economic Circle, enjoying convenient transportation. The company specializes in the R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It passed the ISO 9001:2015 quality management system certification in 2021, was recognized as a Technology-based Small and Medium-sized Enterprise in 2024, and awarded Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. Haohong has a high-level R&D team and a full range of analytical testing instruments and methods. At present, its production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, with an annual production capacity of 1,000 tons. The company focuses on the development of active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies, with an emphasis on high-grade intermediates. Its main products include Bicalutamide, Enzalutamide, Apalutamide, Darolutamide, Abemaciclib, Venetoclax, Macitentan, Empagliflozin, Larotrectinib, Apixaban, Rivaroxaban, Ibrutinib, Ceritinib, Pomalidomide, Lenalidomide, Ivacaftor, Tofacitinib, Cabozantinib, Alectinib, etc. Our products are exported to overseas markets including the United States, Europe, Japan, India, Bangladesh and other regions. The company currently has dozens of high-grade intermediates available for commercial production, and also provides customers with efficient custom synthesis services ranging from gram scale to hundreds of kilograms. Adhering to the corporate philosophy of "Pragmatism, Innovation, Integrity", Haohong is committed to serving global customers with full dedication!
Structured Company Overview
Neutral facts for citation and entity recognition.
- Legal Name
- Haohong Pharmaceutical
- Established
- 2021
- Ownership
- Private
- Production Model
- ODM
- Annual Output
- 1000 tons
- R&D Team
- 30engineers
- Website
- www.haohong-pharma.com
Product Specification Database
Each model is a structured row. No narrative descriptions.
| Name | Model | Type | Material | Applicable Industry | |||||
|---|---|---|---|---|---|---|---|---|---|
| 4-Bromo-2,6-difluoroaniline 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine 2-Bromo-5-formylpyridine 4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole | 4-Bromo-2,6-difluoroaniline 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine 2-Bromo-5-formylpyridine 4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imida | 4-Bromo-2,6-difluoroaniline Main material: Halogenated aniline aromatic compound, fluorine and bromine substituted aniline derivative. 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine Main material: Piperazinyl substituted pyridine amine heterocyclic organic compound. 2-Bromo-5-formylpyridine Main material: Bromo-formyl substituted pyridine heterocyclic fine chemical intermediate. 4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole Main material: Fluorinated benzimidazole derivative containing isopropyl and boronic acid ester groups. 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole Main material: Bromo-fluoro substituted benzimidazole heterocyclic organic synthetic raw material. | Pharmaceutical Manufacturing Industry Anti-cancer Drug & Targeted Therapy Synthesis API Raw Material Production Innovative Drug and Generic Drug R&D Biopharmaceutical & Biomedical Research High-end Fine Chemicals Industry Custom Organic Synthesis & Laboratory Research | ||||||
|
Images
Type 4-Bromo-2,6-difluoroaniline
5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine
2-Bromo-5-formylpyridine
4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imida Applicable Industry Pharmaceutical Manufacturing Industry
Anti-cancer Drug & Targeted Therapy Synthesis
API Raw Material Production
Innovative Drug and Generic Drug R&D
Biopharmaceutical & Biomedical Research
High-end Fine Chemicals Industry
Custom Organic Synthesis & Laboratory Research Params 4-Bromo-2,6-difluoroaniline
CAS: 1868-81-7
Molecular Formula: C₆H₄BrF₂N
Molecular Weight: 207.91
Appearance: White to off-white crystalline solid
Purity: ≥98.0% (HPLC/GC)
Density: 1.768±0.06 g/cm³
Boiling Point: 239.4±35.0 °C
Melting Point: 57–61 °C
Storage: Sealed, dry, keep away from light at 2–8 °C
Application: Abemaciclib pharmaceutical intermediate
5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine
CAS: 398565-53-2
Molecular Formula: C₁₂H₂₀N₄
Molecular Weight: 220.03
Appearance: Off-white to light yellow solid
Purity: ≥98.0% (HPLC)
Boiling Point: 368.5±42.0 °C
Density: 1.124±0.06 g/cm³
Storage: Sealed, low temperature and light protection
Application: Key intermediate for Abemaciclib
2-Bromo-5-formylpyridine
CAS: 100422-52-6
Molecular Formula: C₆H₄BrNO
Molecular Weight: 185.91
Appearance: White to light yellow solid
Purity: ≥98.0% (GC/HPLC)
Melting Point: 78–82 °C
Boiling Point: 286.3±30.0 °C
Storage: Sealed, dry, refrigerated preservation
Application: Heterocyclic intermediate for Abemaciclib synthesis
4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole
CAS: 1356339-86-7
Appearance: White to off-white solid
Purity: ≥98.0% (HPLC)
Storage: Sealed, inert gas protection, 2–8 °C, avoid light
Application: Boronic acid ester intermediate for Abemaciclib
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
CAS: 1356339-85-6
Appearance: White to light beige solid
Purity: ≥98.0% (HPLC)
Storage: Sealed, dry, low temperature and light-proof storage
Application: Core benzimidazole intermediate for Abemaciclib R&D and production Scope |
|||||||||
| 2-(4-Ethylphenyl)-2-methylpropanoic acid 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate | 2-(4-Ethylphenyl)-2-methylpropanoic acid 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate | 2-(4-Ethylphenyl)-2-methylpropanoic acid Main material：Aromatic carboxylic acid organic compound, belongs to alkyl substituted benzoic acid derivative. 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid Main material：Iodine-substituted aromatic carboxylic acid fine organic intermediate. tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate Main material：Indole heterocyclic compound containing cyano and iodo substituents, tert-butyl ester derivative. | Pharmaceutical Industry Anti-cancer & Targeted Therapy Drug Synthesis API Raw Material Manufacturing Innovative Drug & Generic Drug R&D Biopharmaceutical & Biomedical Research High-end Fine Chemicals Industry Custom Organic Synthesis & Laboratory Research | ||||||
|
Images
Type 2-(4-Ethylphenyl)-2-methylpropanoic acid
2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid
tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate Applicable Industry Pharmaceutical Industry
Anti-cancer & Targeted Therapy Drug Synthesis
API Raw Material Manufacturing
Innovative Drug & Generic Drug R&D
Biopharmaceutical & Biomedical Research
High-end Fine Chemicals Industry
Custom Organic Synthesis & Laboratory Research Params 2-(4-Ethylphenyl)-2-methylpropanoic acid
CAS No.：1247119-83-0
Molecular Formula：C₁₂H₁₆O₂
Molecular Weight：192.26 g/mol
Appearance：White to off-white solid
Purity：≥98%
Density：1.047±0.06 g/cm³
Boiling Point：302.8±11.0 °C (760 mmHg)
Storage：2-8°C, sealed
Application：Alectinib intermediate
2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid
CAS No.：1256584-73-2
Molecular Formula：C₁₂H₁₅IO₂
Molecular Weight：318.15 g/mol
Appearance：White to off-white solid
Purity：≥98%
Density：1.547±0.06 g/cm³
Boiling Point：369.6±27.0 °C (760 mmHg)
Storage：2-8°C, protect from light
Application：Alectinib intermediate
tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate
CAS No.：1256584-75-4
Molecular Formula：C₂₅H₂₇IN₂O₂
Molecular Weight：514.40 g/mol
Appearance：White to light yellow solid
Purity：≥98% (HPLC)
Storage：2-8°C, sealed, protect from light
Application：Alectinib key intermediate Scope |
|||||||||
| 2-Fluoro-4-nitrobenzoic acid N-Methyl-2-fluoro-4-nitrobenzamide N-Methyl-2-fluoro-4-aminobenzamide N-Methyl-2-fluoro-4-bromobenzamide Methyl 4-bromo-2-fluorobenzoate 2-Hydroxy-5-nitro-3-(trifluoromethyl)pyridine 5-Amino-3-(trifluoromethyl)pyridinecarbonitrile | 2-Fluoro-4-nitrobenzoic acid N-Methyl-2-fluoro-4-nitrobenzamide N-Methyl-2-fluoro-4-aminobenzamide N-Methyl-2-fluoro-4-bromobenzamide Methyl 4-bromo-2-fluorobenzoate 2-Hydroxy-5-nitro-3-(trifluoromethyl)pyridine 5-Amino-3-(trifluoromethyl)pyridinecarb | 2-Fluoro-4-nitrobenzoic acid Main material: Fluorinated nitrobenzoic acid organic compound N-Methyl-2-fluoro-4-nitrobenzamide Main material: N-methyl fluoronitro benzamide organic intermediate N-Methyl-2-fluoro-4-aminobenzamide Main material: Fluoro-amino substituted benzamide derivative N-Methyl-2-fluoro-4-bromobenzamide Main material: Bromo-fluoro benzamide organic compound Methyl 4-bromo-2-fluorobenzoate Main material: Bromo-fluoro benzoate ester compound 2-Hydroxy-5-nitro-3-(trifluoromethyl)pyridine Main material: Trifluoromethyl pyridine nitro derivative 5-Amino-3-(trifluoromethyl)pyridinecarbonitrile Main material: Amino trifluoromethyl pyridine nitrile compound | 1、Pharmaceutical Industry 2、Anti-cancer & Anti-tumor Drug Manufacturing 3、Targeted Drug & Innovative Drug R&D 4、API & Fine Chemical Synthesis 5、Biotechnology & Biomedical Research 6、Veterinary Drug & Animal Health 7、Custom Organic Synthesis & Laboratory Research | ||||||
|
Images
Type 2-Fluoro-4-nitrobenzoic acid
N-Methyl-2-fluoro-4-nitrobenzamide
N-Methyl-2-fluoro-4-aminobenzamide
N-Methyl-2-fluoro-4-bromobenzamide
Methyl 4-bromo-2-fluorobenzoate
2-Hydroxy-5-nitro-3-(trifluoromethyl)pyridine
5-Amino-3-(trifluoromethyl)pyridinecarb Applicable Industry 1、Pharmaceutical Industry
2、Anti-cancer & Anti-tumor Drug Manufacturing
3、Targeted Drug & Innovative Drug R&D
4、API & Fine Chemical Synthesis
5、Biotechnology & Biomedical Research
6、Veterinary Drug & Animal Health
7、Custom Organic Synthesis & Laboratory Research Params 2-Fluoro-4-nitrobenzoic acid
CAS: 403-24-7
Molecular Formula: C₇H₄FNO₄
Molecular Weight: 185.11
Appearance: White to light yellow solid
Melting Point: 170–176 °C
Boiling Point: 352.5±27 °C (predicted)
Density: 1.568±0.06 g/cm³ (predicted)
Purity: ≥98.0%
Storage: Sealed, dry, stored at room temperature
N-Methyl-2-fluoro-4-nitrobenzamide
CAS: 915087-24-0
Molecular Formula: C₈H₇FN₂O₃
Molecular Weight: 198.15
Appearance: Light yellow to yellow solid
Melting Point: Unavailable
Boiling Point: 337.1±32 °C (predicted)
Density: 1.358 g/cm³
Purity: ≥98.0% (HPLC)
Storage: Sealed, dry, stored at room temperature
N-Methyl-2-fluoro-4-aminobenzamide
CAS: 915087-25-1
Molecular Formula: C₈H₉FN₂O
Molecular Weight: 168.17
Appearance: Off-white solid
Melting Point: 160–163 °C
Boiling Point: Approx. 320 °C (estimated)
Density: Unavailable
Purity: ≥98.0% (HPLC)
Storage: Sealed, dry, stored at room temperature
N-Methyl-2-fluoro-4-bromobenzamide
CAS: 749927-69-3
Molecular Formula: C₈H₇BrFNO
Molecular Weight: 232.05
Appearance: White crystalline powder
Melting Point: Unavailable
Boiling Point: 284.8±30 °C
Density: 1.545±0.06 g/cm³
Purity: ≥98.0% (HPLC)
Storage: Sealed, dry, stored at room temperature
Methyl 4-bromo-2-fluorobenzoate
CAS: 179232-29-2
Molecular Formula: C₈H₆BrFO₂
Molecular Weight: 233.03
Appearance: White to off-white solid
Melting Point: 58–62 °C
Boiling Point: 272.7±25 °C
Density: 1.577±0.06 g/cm³
Purity: ≥98.0% (GC)
Storage: Sealed, dry, stored at room temperature
2-Hydroxy-5-nitro-3-(trifluoromethyl)pyridine
CAS: 99368-66-8
Molecular Formula: C₆H₃F₃N₂O₃
Molecular Weight: 208.09
Appearance: Light yellow solid
Melting Point: 158 °C
Boiling Point: 276.2±40 °C (predicted)
Density: 1.61±0.1 g/cm³ (predicted)
Purity: ≥97%~≥98%
Storage: Sealed, dry, stored at room temperature
5-Amino-3-(trifluoromethyl)pyridinecarbonitrile
CAS: 573762-62-6
CAS: 573762-62-6
Molecular Formula: C₇H₄F₃N₃
Molecular Weight: 187.12
Appearance: Off-white to yellow solid
Melting Point: Unavailable
Boiling Point: 362.2±42 °C (predicted)
Density: 1.45±0.1 g/cm³ (predicted)
Purity: ≥97%~≥99.0%
Storage: Keep away from light, stored at room temperature under inert atmosphere Scope |
|||||||||
Certifications & Compliance
Each record can become a certification entity page.
| Certification | Cert Number | Standard | Authority | Market | Issue Date | Expiry Date | Document |
|---|---|---|---|---|---|---|---|
| Utility Model Patent | 202521269185.6 | Compliant with domestic mechanical equipment & pharmaceutical production industry standards | China National Intellectual Property Administration | CN | 2026-05-28 | 2035-05-28 | |
| Utility Model Patent | 202521280279.3 | Comply with national mechanical equipment & pharmaceutical manufacturing industry standards | China National Intellectual Property Administration | CN | 2026-05-27 | 2035-05-27 | |
| Utility Model Patent | 202521268255.6 | Conform to Chinese national standards for pharmaceutical machinery & general mechanical equipment | China National Intellectual Property Administration | CN | 2026-05-26 | 2035-05-26 | |
| Utility Model Patent | 202520639784.6 | Compliant with national pharmaceutical machinery & mechanical equipment industry standards | China National Intellectual Property Administration | CN | 2025-04-24 | 2035-04-24 | |
| ISO 9001:2015 Quality Management System Certificate | NO:174Q240545R0S | GB/T19001-2016(ISO9001:2015) | Shandong Guojian Certification Co., Ltd. | Global | 2024-11-26 | 2027-11-25 |
Applications & Industries
Taxonomy-backed tags to form industry ↔ supplier ↔ product relationships.
| Industry | Country | Working Condition | Project Type | Function | Operation Mode | Special Requirement | Matched Equipment |
|---|---|---|---|---|---|---|---|
| Pharmaceutical Industry Production of human-use API, generic drugs, innovative drugs, targeted drugs, anti-cancer drugs, anti-viral drugs and anti-infective drugs 2 Veterinary and Animal Health Industry 3 Fine Chemical Industry 4Pesticide Industry 5 Biotechnology and R&D Industry 6 Medical-grade Raw Materials for Cosmetics & Daily Chemicals 7Health Supplement Industry | US,AU,CA,CN,DE,FR,GB,KR,MY,SE,IN,JP,BD | Fully enclosed reaction systems to prevent air exposure, suitable for sterile and oxygen-free production environments. | 1Anti-cancer Drug Projects 2Anti-viral Drug Projects 3 Anti-infective & Anti-inflammatory Projects 4Cardiovascular and Cerebrovascular Drug Projects 5 Hypoglycemic and Lipid-lowering Drug Projects 6 Veterinary Health Drug Projects 7New Drug R&D Custom Projects | Pharmaceutical intermediates are key intermediate raw materials between the fine chemical and pharmaceutical industries. As pre-semi-finished products for synthesizing Active Pharmaceutical Ingredients (API), they undergo further chemical processing from basic chemical raw materials. They provide pharmaceutical enterprises with structurally mature and high-purity intermediate compounds, greatly simplifying the R&D and production processes of new drugs and APIs, shortening synthetic procedures, and reducing production costs as well as environmental and safety pressures. They serve as indispensable core upstream supporting materials for the R&D and large-scale production of various human and veterinary medicines such as anti-cancer, anti-viral and anti-infective drugs. | Automated & Program-controlled Operation | Special Requirements for Pharmaceutical Intermediates Production All material contact parts adopt 316L stainless steel, borosilicate glass and PTFE lining, anti-corrosion and heavy metal free. Production workshop meets Class C/D clean grade, closed production process. Full explosion-proof and anti-static design with nitrogen protection system. Strict temperature & humidity control, low-temperature production to avoid oxidation and decomposition. Equipped with tail gas absorption and wastewater pretreatment system for fluorine, bromine and iodine containing intermediates. Strict quality control: purity ≥98%–99%, HPLC/GC/COA full batch inspection. Vacuum sealed packaging, low-temperature and away-from-light storage & transportation. Complete production qualification and batch traceability system. | Key Supporting Equipment for Pharmaceutical Intermediates (Abemaciclib etc.) Reaction: Double-layer glass reactor (10L–200L), 316L/stainless steel reactor, glass-lined reactor. Purification: Rotary evaporator (10L–100L), centrifuge, chromatography column, plate & frame filter press. Drying: Vacuum drying oven, spray dryer, double-cone rotary vacuum dryer. Transfer & Storage: Sanitary diaphragm pump, magnetic pump, sealed 316L storage tank. Temperature & Vacuum: Low-temperature circulator (-80℃), thermal oil heater, vacuum pump. Testing: HPLC, GC, IR, melting point apparatus. Safety & EHS: Explosion-proof system, tail gas absorption tower, wastewater pretreatment. |
Industries (1) → Products (3 models) → Certifications (5)
Manufacturing Capabilities
Core processes and equipment available in-house.
🎨
Customization
Structural Customization Purity & Specification Customization Process Route Customization Capacity & Batch Customization Packaging & Standard Customization R&D and OEM/ODM Customization
📊
Monthly Capacity
100MT
⏱️
Lead Time
Tailor-made Services
🌍
Export Markets
At present, our export services cover the United States, Europe, India, Bangladesh and other countries and regions.
💬
After Sales
1.Full Support of Quality Inspection Documents 2.Technical & Process Consulting Support 3.Logistics & Customs Clearance After-sales 4.Quality Dispute Compensation & Replacement 5.Sample Re-inspection & Third-party Testing 6.Stable Supply & Production Scheduling Guarantee 7.Customized R&D & Iteration Service
🧪
Quality Control
1 Appearance and Property Inspection 2 Core Chromatographic Testing 3 Structural Qualitative Identification 4 Physical and Chemical Index Testing 5 Heavy Metal and Impurity Testing 6 Microbiological Testing 7 Factory Delivery Supporting Documents
Project References / Cases
Verified project records. Client names anonymized where requested.
| Client Type | Country | Quantity | Application | Duration | Result | Highlight |
|---|---|---|---|---|---|---|
| Top-tier Pharmaceutical Group | US,AE,AU,BD,CA,CN,DE,FR,KR,SA,GB,IN,SG,SE | 200 | which are synthesized and processed into final finished medicines. | 12–24 months under specified storage conditions | 1High reaction yield reduces the production cost of finished pharmaceuticals. 2Low levels of impurities, heavy metals and residual solvents minimize drug safety risks. 3Stable quality across batches improves the consistency of customers’ pharmaceutical production. 4Simplified downstream synthesis processes shorten drug development cycles. 5Accelerates the drug registration process. | Ultra‑high purity with strictly controlled impurities, heavy metals and residual solvents. Consistent quality batch‑to‑batch, stable crystal form and particle size. Strict compliance with ICH, GMP and international pharmaceutical standards. Stable large‑scale production capacity and reliable supply chain. Customizable R&D support for API synthesis and drug registration. |
Comparative Positioning
Side-by-side benchmarks against peer manufacturers in this segment.
| Compared To | Difference | Performance Gap | Best For | Cost Difference | Efficiency |
|---|---|---|---|---|---|
| counterpart | 1.Timely delivery 2.High product purity 3.Stable batch quality 4.Supported by full technical documents, fully compliant with regulations. 5.Full adherence to client-specified index values. | 1.Purity is 0.02 higher than industry peers. 2.Batch quality stability is 10% above the industry average. 3.Complete set of technical documents in full compliance. | Anti-cancer drug API synthesis, targeted drug development, high-purity fine chemical production, custom R&D projects | Combining in-depth R&D and self-owned factories delivers lower costs compared with the market average. | Optimized synthetic routes improve production efficiency and reduce solvent consumption |
Risk & Trust Signals
Aggregated data-driven indicators. Not an endorsement.
✓ Overall Trust Score
78/100
Based on 14 verified signals
✓ Positive Signals
Trade RegistrationVerified
Alibaba Gold SupplierYes (5+ yrs)
Audited by 3rd Party2024
On-time Delivery Rate94%
⚠ Risk Items
There are many instances of delayed delivery within the sector.Haohong Pharmaceuticals: Sufficient regular stock & timely restocking. Digitalized product management ensures prompt supply to customers.
Enterprise MeasureMaintain safety stock levels, implement real-time inventory monitoring, and optimize production scheduling
ℹ Additional Info
Last Verified2026-06-10 17:21:55
Data SourcesAICPA, Alibaba, TÜV
Profile Completeness91%
Purchase & Trade Information
Trading terms and procurement details.
ℹ Purchase Details
MOQCustomized Services
Delivery MethodWe offer full-range international trade delivery terms including EXW, FOB, CFR, CIF, air freight, international express, as well as DDP/DDU door-to-door services.
AcceptancePre-shipment test
Payment Terms50/50
Product Comparison
Comparative analysis against alternative solutions.
| Compared To | Difference | Performance Gap | Best For | Cost Difference | Efficiency |
|---|---|---|---|---|---|
| counterpart | 1.Timely delivery 2.High product purity 3.Stable batch quality 4.Supported by full technical documents, fully compliant with regulations. 5.Full adherence to client-specified index values. | 1.Purity is 0.02 higher than industry peers. 2.Batch quality stability is 10% above the industry average. 3.Complete set of technical documents in full compliance. | Anti-cancer drug API synthesis, targeted drug development, high-purity fine chemical production, custom R&D projects | Combining in-depth R&D and self-owned factories delivers lower costs compared with the market average. | Optimized synthetic routes improve production efficiency and reduce solvent consumption |